The impact of MET, IGF-1, IGF1R expression and EGFR mutations on survival of patients with non-small-cell lung cancer

about

ALK and IGF-1R as independent targets in crizotinib resistant lung cancer.Prognostic value of MET copy number gain in non-small-cell lung cancer: an updated meta-analysis.HSP90: A Novel Target Gene of miRNA-628-3p in A549 Cells.

P2860

Q42639671-127D74DF-199A-4D65-99D9-4B57CA476607 Q55145107-18C14023-19D4-4551-852E-DAC64FA6C7DC Q55280225-101C4495-F6A6-4145-93AD-63D9B9E11E39

P2860

The impact of MET, IGF-1, IGF1R expression and EGFR mutations on survival of patients with non-small-cell lung cancer

Item

http://www.wikidata.org/entity/Q42337044

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

The impact of MET, IGF-1, IGF1 ...... ith non-small-cell lung cancer

@en

The impact of MET, IGF-1, IGF1 ...... ith non-small-cell lung cancer

@nl

type

Item

label

The impact of MET, IGF-1, IGF1 ...... ith non-small-cell lung cancer

@en

The impact of MET, IGF-1, IGF1 ...... ith non-small-cell lung cancer

@nl

prefLabel

The impact of MET, IGF-1, IGF1 ...... ith non-small-cell lung cancer

@en

The impact of MET, IGF-1, IGF1 ...... ith non-small-cell lung cancer

@nl

P1476

The impact of MET, IGF-1, IGF1 ...... ith non-small-cell lung cancer

@en

P2093

Elin Richardsen

http://www.w3.org/2001/XMLSchema#string

Lill-Tove Busund

http://www.w3.org/2001/XMLSchema#string

Mehrdad Khanehkenari

http://www.w3.org/2001/XMLSchema#string

Roy M Bremnes

http://www.w3.org/2001/XMLSchema#string

Sigve Andersen

http://www.w3.org/2001/XMLSchema#string

Tom Donnem

http://www.w3.org/2001/XMLSchema#string

P2860

The DNA sequence of human chromosome 7

COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer

Understanding and Targeting MET Signaling in Solid Tumors - Are We There Yet?

MET gene copy number predicts worse overall survival in patients with non-small cell lung cancer (NSCLC); a systematic review and meta-analysis

Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.

Response to Crizotinib Observed in Lung Adenocarcinoma with MET Copy Number Gain but without a High-Level MET/CEP7 Ratio, MET Overexpression, or Exon 14 Splicing Mutations.

MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.

Global cancer statistics, 2012

Resistance mechanisms after tyrosine kinase inhibitors afatinib and crizotinib in non-small cell lung cancer, a review of the literature

Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase

P304

e0181527

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0181527

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Samer Al-Saad

Thomas K Kilvaer

P577

2017-07-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28742836

http://www.w3.org/2001/XMLSchema#string

P932

5526580

http://www.w3.org/2001/XMLSchema#string

The impact of MET, IGF-1, IGF1R expression and EGFR mutations on survival of patients with non-small-cell lung cancer

about

P2860

P2860

The impact of MET, IGF-1, IGF1R expression and EGFR mutations on survival of patients with non-small-cell lung cancer

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932